HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. [electronic resource]
Producer: 20100928Description: 499-505; discussion 505-6 p. digitalISSN:- 1528-1140
- Adenocarcinoma -- drug therapy
- Biomarkers, Tumor -- metabolism
- Combined Modality Therapy
- Cyclooxygenase 2 -- metabolism
- Deoxycytidine -- analogs & derivatives
- ELAV Proteins -- metabolism
- ELAV-Like Protein 2
- Female
- Humans
- Immunoenzyme Techniques
- Male
- Microarray Analysis
- Neoplasm Staging
- Pancreatic Neoplasms -- drug therapy
- Prognosis
- Proportional Hazards Models
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Analysis
- Vascular Endothelial Growth Factor A -- metabolism
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.